Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Hikma Overtakes Fresenius In US Injectables

Injectables Growth Across Regions In 2021 Accompanies Expansion Through Acquisitions

02 Mar 2022

• By Dave Wallace

Competition winners podium 1 2 3 — Hikma has jumped into second place in US injectables volumes • Source: Enrico Mantegazza / Alamy Stock Photo

Related Content

Hikma Buys Injectables Specialist Custopharm In $400m+ Deal

27 Sep 2021

Fresenius Puts Kabi At The Top As It Ponders Best Use Of Cash

24 Feb 2022

Hikma Adds Remsima SC To Celltrion MENA Collaboration

09 Feb 2022

Hikma Seeks To Meet Demand For 503B Compounding In US

25 Jan 2022

Hikma Highlights Long-Term Importance Of Biosimilars

24 Jan 2022

Hikma Buys Teligent Assets To Expand Into Canada

17 Jan 2022

Hikma Warns Of Renewed Pricing Pressure On US Generics

03 Mar 2022

Fresenius Kabi: No Launches From US Melrose Park Facility In 2021

25 Feb 2021

Related Companies

Hikma Pharmaceuticals plc

Additional Topics

United States Sales & Earnings Strategy Generic Drugs Biosimilars BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.